RxDoctor Payments Data

Khaled Janom, MD

Internal Medicine · Detroit, MINPI 1528592128

Payments from drug & device makers

$529in general payments, 2019–2025

Across 29 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$135
  • Amgen$82
  • Travere Therapeutics, Inc.$60
  • GSK$58
  • Otsuka America Pharmaceutical, Inc.$42
  • Novartis$40
  • plus $113 from 5 others

What the payments were for

  • Food & beverage$41078%
  • Education$11922%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$529 in reported general payments places this provider in the 65th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$196,390
Medicare patients
294
Services billed
1,412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide29$85,624
AuryxiaFerric Citrate16$28,243
Lanthanum Carbonate15$18,853
Sevelamer Carbonate70$13,454
ClinisolParenteral Amino Acid 15% No.547$5,683
Torsemide87$2,449
Calcium Acetate29$1,676
Tamsulosin Hcl78$1,339
Bumetanide29$1,133
Telmisartan26$871
Carvedilol98$851
Amlodipine Besylate171$844
Calcitriol49$767
Potassium Chloride38$753
Chlorthalidone36$702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$18$85,62429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →